viewQuantum Computing Inc.

Quantum Computing adds medical expert Dr Michael Liebman to advisory board

His research is on computational models of disease progression, clinical pathway modeling, and disease stratification from a clinical perspective

Quantum Computing Inc. -
Liebman’s work utilizes systems-based approaches and design thinking to represent and analyze risk-benefit analysis in pharmaceutical development and healthcare

Quantum Computing Inc (OTCMKTS:QUBT) is adding key medical expertise to its technical advisory board.

The Leesburg, Virginia-based technology firm said Dr Michael Liebman is joining its advisory board to add a “unique perspective” that will allow the company to apply its techniques to the pharmaceutical and healthcare sectors.

Liebman’s research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective. 

READ: Quantum Computing appoints physics expert Nicholas Chancellor to advisory board

“(Liebman) applies his diverse background to identify and address the challenges of real-world clinical practice and real-world patients and how these impact healthcare and the development of both diagnostics and therapeutics,” said Quantum’s CEO Robert Liscouski in a statement.

“He sees that the application of QCI’s unique approach and its highly qualified team in quantum computing to knowledge management and analysis in these areas can bring perspectives and results that were previously not attainable because of the complexity of the data and systems.”

Liebman’s work utilizes systems-based approaches and design thinking to represent and analyze risk-benefit analysis in pharmaceutical development and healthcare, Quantum told shareholders.

The new advisory board member is working closely with Quantum’s applications development team to “ensure its next product is closely aligned with the needs of the pharmaceutical industry as it moves into quantum computing,” Steve Reinhardt, Quantum’s vice president of product development said in a statement.

Liebman himself said that the combination of Quantum’s technical team and his own medical background will allow the company to make a “significant contribution” to the field.

“Billions of R&D dollars are being invested by pharmaceutical companies to develop drugs for specific populations with specific diseases,” Liebman said in a statement.

“Based on my research, I believe quantum computing techniques will have a significant impact on positive outcomes, resulting in better drug treatments and greater return on investment.”

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Quantum Computing Inc.

Price: 2.77 USD

Market: OTCQB
Market Cap: $22.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Quantum Computing Inc. named herein, including the promotion by the Company of Quantum Computing Inc. in any Content on the Site, the Company...



UGE International sees strong 1st quarter as the solar company books...

UGE International (TSXV: UGE) (OTCQB: UGEIF) CEO Nick Blitterswyk joined Steve Darling from Proactive to discuss the company's first-quarter numbers that saw them significantly secure new projects. Blitterswyk discusses that new business and what he sees as a key market outside of...

1 hour, 5 minutes ago

2 min read